Inflammatory Responses

A New York-based biotechnology company has received a $4 million grant from the NIH’s National Institute on Aging to advance a novel intranasal therapeutic to treat Alzheimer’s disease, according to a press release from the manufacturer.

Elevating nicotinamide adenine dinucleotide with nicotinamide riboside supplementation reduced inflammation in both healthy controls and patients with psoriasis, according to findings from a clinical study.